Multiplexed Measurement of Disease Biomarkers by Mass Spectometry (MRM) for Predictive and Prognostic Purposes SELECTBIO
The application of a range of proteomics strategies has resulted in the discovery of very large numbers of potential new protein biomarkers but few have reached clinical utility for (a) understanding the molecular mechanisms of disease pathogenesis, (b) identifying new therapeutic targets, or (c) implementing biomarker based personalised treatment. Some of the challenges faced in the protein biomarker development process and potential solutions will be described from our recent studies on prostate cancer and psoriatic arthritis. In these on-going collaborative projects we are developing a ‘clinical question focused’ pipeline for candidate protein biomarker assembly and validation of 'protein biomarker signatures' by multiple reaction monitoring (MRM). The potential of this approach for the delivery of more personalised patient treatment will be discussed.